---
title: "Yabao Pharmaceutical Group Co., Ltd. (600351.SH)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/600351.SH.md"
symbol: "600351.SH"
name: "Yabao Pharmaceutical Group Co., Ltd."
industry: "Pharmaceuticals"
datetime: "2026-05-20T11:31:40.969Z"
locales:
  - [en](https://longbridge.com/en/quote/600351.SH.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/600351.SH.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/600351.SH.md)
---

# Yabao Pharmaceutical Group Co., Ltd. (600351.SH)

## Company Overview

Yabao Pharmaceutical Group Co., Ltd researches, develops, manufactures, and sells Chinese and Western medicines, and pharmaceutical packaging materials in China and internationally. It provides pediatric products, cardiovascular and cerebrovascular products, endocrine products, women's health products, patches, and general health products. Yabao Pharmaceutical Group Co., Ltd was founded in 1978 and is based in Beijing, China.

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | CN Market |
| Website | [www.yabao.com.cn](https://www.yabao.com.cn) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: B
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-20T04:30:09.000Z

**Overall: B (0.40)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 55 / 215 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: B

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -13.12% |  |
| Net Profit YoY | 34.38% |  |
| P/B Ratio | 1.60 |  |
| Dividend Ratio | 7.64% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 4568391698.86 |  |
| Revenue | 2201461252.67 |  |

#### Multi Score Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 11.02% | B |
| Profit Margin | 14.53% | B |
| Gross Margin | 53.24% | B |
| Revenue YoY | -13.12% | E |
| Net Profit YoY | 34.38% | B |
| Total Assets YoY | -8.14% | E |
| Net Assets YoY | -5.09% | D |
| Cash Flow Margin | 192.80% | B |
| OCF YoY | -13.12% | E |
| Turnover | 0.64 | B |
| Gearing Ratio | 14.79% | A |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Yabao Pharmaceutical Group Co., Ltd.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-13.12%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "34.38%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "1.60",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "7.64%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "4568391698.86",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "2201461252.67",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "B",
      "indicators": [
        {
          "name": "ROE",
          "value": "11.02%",
          "rating": "B"
        },
        {
          "name": "Profit Margin",
          "value": "14.53%",
          "rating": "B"
        },
        {
          "name": "Gross Margin",
          "value": "53.24%",
          "rating": "B"
        },
        {
          "name": "Revenue YoY",
          "value": "-13.12%",
          "rating": "E"
        },
        {
          "name": "Net Profit YoY",
          "value": "34.38%",
          "rating": "B"
        },
        {
          "name": "Total Assets YoY",
          "value": "-8.14%",
          "rating": "E"
        },
        {
          "name": "Net Assets YoY",
          "value": "-5.09%",
          "rating": "D"
        },
        {
          "name": "Cash Flow Margin",
          "value": "192.80%",
          "rating": "B"
        },
        {
          "name": "OCF YoY",
          "value": "-13.12%",
          "rating": "E"
        },
        {
          "name": "Turnover",
          "value": "0.64",
          "rating": "B"
        },
        {
          "name": "Gearing Ratio",
          "value": "14.79%",
          "rating": "A"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 14.28 | 11/215 | 21.06 | 20.50 | 18.58 |
| PB | 1.60 | 52/215 | 1.72 | 1.68 | 1.60 |
| PS (TTM) | 2.08 | 35/215 | 2.08 | 2.02 | 1.92 |
| Dividend Yield | 7.64% | 4/215 | 7.48% | 4.59% | 4.37% |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Allist (688578.SH) | A | A | B | A | B | A |
| 02 | Xingqi Pharmaceutical (300573.SZ) | A | A | A | A | B | A |
| 03 | Hengrui Pharma (600276.SH) | A | B | C | A | B | B |
| 04 | Yunnan Baiyao (000538.SZ) | B | C | B | B | C | B |
| 05 | Haisco (002653.SZ) | A | A | B | B | B | B |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/600351.SH/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/600351.SH/norm.md)
- [Related News](https://longbridge.com/en/quote/600351.SH/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/600351.SH/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**